Biodexa raises $2.3M via warrant exercise agreement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Biodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026 8:00 AM EDTBiodexa Enters Into Warrant Exercise Transaction for $2.3 Million in Gross Proceeds
September 15, 2026
Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX) (Biodexa or the Company), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 2,204,218 American Depositary Shares (ADSs) of the Company (the Existing Warrants) at an exercise price of $1.05 for gross cash proceeds of approximately $2.3 million, before deducting financial advisor fees... More
